Faster PET scans and breath-hold examinations are already improving imaging for patients who are in pain or unable to remain still. And Switzerland is one country that offers advanced technology, research funding, and an extensive PET network.
Dr. Antoine Leimgruber, director of development for nuclear medicine at Swiss Medical Network in Genolier argues that regulations designed for conventional drugs do not always reflect the specific characteristics of low-dose radiopharmaceuticals.
From facilitating early-phase trials and expanding outpatient therapy to investing intelligently in equipment and turning promising biomarkers into actionable clinical decisions, key questions remain.
Watch the interview to learn why Leimgruber believes technology, AI, policy, and ethically designed regulation must evolve together and read the accompanying Q&A for a deeper dive.
